Literature DB >> 21574063

Expression and purification of a natural N-terminal pre-ligand assembly domain of tumor necrosis factor receptor 1 (TNFR1 PLAD) and preliminary activity determination.

Jin Cao1, Fang Meng, Xiangdong Gao, Hongxia Dong, Wenbing Yao.   

Abstract

A domain at the NH(2) terminal (N-terminal) of tumor necrosis factor receptor (TNFR) termed the pre-ligand binding assembly domain (PLAD). The finding that PLAD can mediate a selective TNFR assembly in previously researches provides a novel target to the prevention of TNFR signaling in immune-mediated inflammatory diseases (IMID). In this study, a natural N-terminal TNFR1 PLAD was obtained for the first time through the methods of GST-tag fusion protein expression and enterokinase cleavage. After purification with a Q Sepharose Fast Flow column, a natural N-terminal TNFR1 PLAD which purity was up to 95%, was obtained and was identified using Nano LC-ECI-MS/MS. Secondary structure analysis of PLAD was carried out using circular dichroism spectra (CD). After that, the TNFR1 PLAD in vitro anti-TNFα activity and the specific TNFR1 affinity were determined. The results proved that the natural N-terminal TNFR1 PLAD can selectively inhibit TNFα bioactivity mainly through TNFR1. It infers an effective and safe strategy for treating variety of IMID with a low risk of side effects in future.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21574063     DOI: 10.1007/s10930-011-9330-4

Source DB:  PubMed          Journal:  Protein J        ISSN: 1572-3887            Impact factor:   2.371


  26 in total

1.  A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling.

Authors:  F K Chan; H J Chun; L Zheng; R M Siegel; K L Bui; M J Lenardo
Journal:  Science       Date:  2000-06-30       Impact factor: 47.728

2.  Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases.

Authors:  Marc Feldmann; Ravinder N Maini
Journal:  Nat Med       Date:  2003-10       Impact factor: 53.440

Review 3.  New concepts in the treatment of rheumatoid arthritis.

Authors:  Raphaela Goldbach-Mansky; Peter E Lipsky
Journal:  Annu Rev Med       Date:  2001-12-03       Impact factor: 13.739

Review 4.  The pre-ligand binding assembly domain: a potential target of inhibition of tumour necrosis factor receptor function.

Authors:  F K Chan
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

5.  Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon.

Authors:  B B Aggarwal; T E Eessalu; P E Hass
Journal:  Nature       Date:  1985 Dec 19-1986 Jan 1       Impact factor: 49.962

Review 6.  Development of anti-TNF therapy for rheumatoid arthritis.

Authors:  Marc Feldmann
Journal:  Nat Rev Immunol       Date:  2002-05       Impact factor: 53.106

7.  Drug-induced systemic lupus erythematosus associated with etanercept therapy.

Authors:  Najia Shakoor; Margaret Michalska; Charlotte A Harris; Joel A Block
Journal:  Lancet       Date:  2002-02-16       Impact factor: 79.321

Review 8.  TNF receptor subtype signalling: differences and cellular consequences.

Authors:  David J MacEwan
Journal:  Cell Signal       Date:  2002-06       Impact factor: 4.315

9.  Targeting TNF-alpha receptors for neurotherapeutics.

Authors:  Wayne Chadwick; Tim Magnus; Bronwen Martin; Aleksander Keselman; Mark P Mattson; Stuart Maudsley
Journal:  Trends Neurosci       Date:  2008-09-04       Impact factor: 13.837

10.  Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.

Authors:  Juan J Gómez-Reino; Loreto Carmona; Vicente Rodríguez Valverde; Emilio Martín Mola; Maria Dolores Montero
Journal:  Arthritis Rheum       Date:  2003-08
View more
  7 in total

1.  Binding Studies of TNF Receptor Superfamily (TNFRSF) Receptors on Intact Cells.

Authors:  Isabell Lang; Simone Füllsack; Agnes Wyzgol; Andrea Fick; Johannes Trebing; José Antonio Carmona Arana; Viktoria Schäfer; Daniela Weisenberger; Harald Wajant
Journal:  J Biol Chem       Date:  2015-12-31       Impact factor: 5.157

2.  Noncompetitive inhibitors of TNFR1 probe conformational activation states.

Authors:  Chih Hung Lo; Tory M Schaaf; Benjamin D Grant; Colin Kin-Wye Lim; Prachi Bawaskar; Courtney C Aldrich; David D Thomas; Jonathan N Sachs
Journal:  Sci Signal       Date:  2019-07-30       Impact factor: 8.192

Review 3.  Tumor Necrosis Factor Receptor 2 (TNFR2): An Emerging Target in Cancer Therapy.

Authors:  Juliane Medler; Kirstin Kucka; Harald Wajant
Journal:  Cancers (Basel)       Date:  2022-05-25       Impact factor: 6.575

Review 4.  Principles of antibody-mediated TNF receptor activation.

Authors:  H Wajant
Journal:  Cell Death Differ       Date:  2015-08-21       Impact factor: 15.828

Review 5.  CD95 Structure, Aggregation and Cell Signaling.

Authors:  Nicolas Levoin; Mickael Jean; Patrick Legembre
Journal:  Front Cell Dev Biol       Date:  2020-05-05

Review 6.  Receptor Oligomerization and Its Relevance for Signaling by Receptors of the Tumor Necrosis Factor Receptor Superfamily.

Authors:  Kirstin Kucka; Harald Wajant
Journal:  Front Cell Dev Biol       Date:  2021-02-11

7.  TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity.

Authors:  Xiaojie Yu; Sonya James; James H Felce; Blanka Kellermayer; David A Johnston; H T Claude Chan; Christine A Penfold; Jinny Kim; Tatyana Inzhelevskaya; C Ian Mockridge; Yasunori Watanabe; Max Crispin; Ruth R French; Patrick J Duriez; Leon R Douglas; Martin J Glennie; Mark S Cragg
Journal:  Commun Biol       Date:  2021-06-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.